PRINCETON, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that it is scheduled to present at the BIO CEO and Investor Conference at 1:30 PM Eastern Time on February 15, 2006. The conference is being held at The Waldorf=Astoria Hotel in New York. Medarex’s presentation will be webcast live and will be available for replay through the Webcast page in the Investor Relations section of the Medarex website via the Internet at www.medarex.com.
In addition, Medarex plans to participate in the “Cancer: New Mechanisms of Action for Cancer Treatment” Focus Session at 4:00 PM Eastern Time on February 14, 2006. An archive webcast of the Focus Session is expected to be made available after the end of the event through the BIO CEO and Investor Conference website via the Internet at www.ceo.bio.org.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Thirty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with four of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
Medarex, Inc.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216; orJean Mantuano, Corporate Communications (media), +1-609-430-2880, x2221,both of Medarex
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html/
